Abstract
Purpose. The role of arginine vasopressin in heart failure and the use of vasopressin receptor antagonists in the treatment of heart failure are reviewed. Summary. Arginine vasopressin (AVP) functions in the regulation of plasma osmolarity and blood pressure. In heart failure, AVP worsens heart failure by causing vasoconstriction of arteries and veins, potentially contributing to remodeling of the left ventricle and causing fluid retention and worsening of hyponatremia. Two V2-receptor antagonists, tolvaptan and lixivaptan, and one combined V1a- and V2-receptor antagonist, conivaptan, have shown promise for use in patients with heart failure. All three agents have been shown to increase free water excretion and increase serum sodium levels while maintaining serum potassium levels. They have not been shown to decrease renal function or the glomerular filtration rate and are well tolerated, with thirst being the major adverse effect during clinical trials. Because of their effects on sodium, vasopressin antagonists need to be carefully monitored to ensure that serum sodium levels do not increase too quickly and put the patient at risk for overcorrection or osmotic demyelination syndrome. In addition, patients need to be monitored for signs of dehydration secondary to increased urine excretion. To date, studies have not consistently shown improvements in patient symptoms or weight reduction. However, early data suggest that at least one agent, tolvaptan, does not alter mortality. Conclusion. Based on data from available clinical trials, vasopressin antagonists may offer a new treatment option for patients with congestive heart failure. However, these agents do not currently appear to delay the progression of heart failure or decrease mortality.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 807-817 |
| Number of pages | 11 |
| Journal | American Journal of Health-System Pharmacy |
| Volume | 65 |
| Issue number | 9 |
| DOIs | |
| State | Published - May 1 2008 |
| Externally published | Yes |
Fingerprint
Keywords
- Cardiac drugs
- Conivaptan
- Heart failure
- Lixivaptan
- Mechanism of action
- Tolvaptan
- Toxicity
- Vasopressin antagonists
ASJC Scopus subject areas
- Pharmaceutical Science
- Leadership and Management
Cite this
Vasopressin-receptor antagonists in heart failure. / Schweiger, Teresa A.; Zdanowicz, Martin.
In: American Journal of Health-System Pharmacy, Vol. 65, No. 9, 01.05.2008, p. 807-817.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Vasopressin-receptor antagonists in heart failure
AU - Schweiger, Teresa A.
AU - Zdanowicz, Martin
PY - 2008/5/1
Y1 - 2008/5/1
N2 - Purpose. The role of arginine vasopressin in heart failure and the use of vasopressin receptor antagonists in the treatment of heart failure are reviewed. Summary. Arginine vasopressin (AVP) functions in the regulation of plasma osmolarity and blood pressure. In heart failure, AVP worsens heart failure by causing vasoconstriction of arteries and veins, potentially contributing to remodeling of the left ventricle and causing fluid retention and worsening of hyponatremia. Two V2-receptor antagonists, tolvaptan and lixivaptan, and one combined V1a- and V2-receptor antagonist, conivaptan, have shown promise for use in patients with heart failure. All three agents have been shown to increase free water excretion and increase serum sodium levels while maintaining serum potassium levels. They have not been shown to decrease renal function or the glomerular filtration rate and are well tolerated, with thirst being the major adverse effect during clinical trials. Because of their effects on sodium, vasopressin antagonists need to be carefully monitored to ensure that serum sodium levels do not increase too quickly and put the patient at risk for overcorrection or osmotic demyelination syndrome. In addition, patients need to be monitored for signs of dehydration secondary to increased urine excretion. To date, studies have not consistently shown improvements in patient symptoms or weight reduction. However, early data suggest that at least one agent, tolvaptan, does not alter mortality. Conclusion. Based on data from available clinical trials, vasopressin antagonists may offer a new treatment option for patients with congestive heart failure. However, these agents do not currently appear to delay the progression of heart failure or decrease mortality.
AB - Purpose. The role of arginine vasopressin in heart failure and the use of vasopressin receptor antagonists in the treatment of heart failure are reviewed. Summary. Arginine vasopressin (AVP) functions in the regulation of plasma osmolarity and blood pressure. In heart failure, AVP worsens heart failure by causing vasoconstriction of arteries and veins, potentially contributing to remodeling of the left ventricle and causing fluid retention and worsening of hyponatremia. Two V2-receptor antagonists, tolvaptan and lixivaptan, and one combined V1a- and V2-receptor antagonist, conivaptan, have shown promise for use in patients with heart failure. All three agents have been shown to increase free water excretion and increase serum sodium levels while maintaining serum potassium levels. They have not been shown to decrease renal function or the glomerular filtration rate and are well tolerated, with thirst being the major adverse effect during clinical trials. Because of their effects on sodium, vasopressin antagonists need to be carefully monitored to ensure that serum sodium levels do not increase too quickly and put the patient at risk for overcorrection or osmotic demyelination syndrome. In addition, patients need to be monitored for signs of dehydration secondary to increased urine excretion. To date, studies have not consistently shown improvements in patient symptoms or weight reduction. However, early data suggest that at least one agent, tolvaptan, does not alter mortality. Conclusion. Based on data from available clinical trials, vasopressin antagonists may offer a new treatment option for patients with congestive heart failure. However, these agents do not currently appear to delay the progression of heart failure or decrease mortality.
KW - Cardiac drugs
KW - Conivaptan
KW - Heart failure
KW - Lixivaptan
KW - Mechanism of action
KW - Tolvaptan
KW - Toxicity
KW - Vasopressin antagonists
UR - http://www.scopus.com/inward/record.url?scp=43449094344&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=43449094344&partnerID=8YFLogxK
U2 - 10.2146/ajhp070132
DO - 10.2146/ajhp070132
M3 - Article
C2 - 18436727
AN - SCOPUS:43449094344
VL - 65
SP - 807
EP - 817
JO - American Journal of Health-System Pharmacy
JF - American Journal of Health-System Pharmacy
SN - 1079-2082
IS - 9
ER -